Genentech Sues Sandoz Over Generic Lung Disease Drug
Genentech says Sandoz has cost it potentially billions in lost profits by selling a generic version of the lung disease drug Esbriet "despite being well aware" of Genentech's patent on the...To view the full article, register now.
Already a subscriber? Click here to view full article